We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Your guide to a disrupted world
Add this topic to your myFT Digest for news straight to your inbox
Top finance director ousted after one day in job following emergence of probe at former employer
Exit of Jorge Gomez after only a day in the job is latest in string of executives to leave biotech group
Tishman Speyer, Bellco and Brookfield among those increasing their bets on expanding life sciences
Rout revives fears of American buyers swooping on the continent’s start-ups
University spinout is developing two vaccines to help prevent future pandemics
Sierra’s bone marrow cancer treatment had positive clinical trial results in January
The continent is eager to capitalise on BioNTech’s Covid-19 success — but matching the scale of US hubs will be hard
US drugmaker seeks more tie-ups after existing collaboration yields new cancer treatment
Overstating promise of emerging field threatens to skew valuations and progress in biotech sector
Struggle to raise fresh funds as ‘tourist’ investors lured by Covid successes dump shares
Biotech groups face cash crunch after a ‘bloodbath’ in the stock market as investors dump shares
Chief executive deSouza attacks regulatory intervention over cancer test company
Hopes early warning system will give policymakers and vaccine producers more time to address health risks
Pharma executives say threats of tougher scrutiny put future of sector at risk
Good venture capitalism should build companies up, developing medicines that deliver public good and profit
Quell to start clinical trials of product designed to prevent rejection of liver transplants
University spinout’s portable DNA sequencer has proved invaluable in tracking the global spread of coronavirus
Isomorphic Labs will build on DeepMind’s research and will be headed by Demis Hassabis
US regulatory shake-up will mainly effect people who would otherwise have gone without
A turnround is under way — but British investors may be missing a trick
GIC acquires stake for more than 10 times its worth in 2016
Acquisition will expand US pharmaceutical company’s pipeline of cardiovascular treatments
The pandemic highlighted weaknesses in global health systems but has spurred a powerful response. Plus: how climate change risks backsliding on gains against malaria; long Covid perplexes researchers; new HIV treatments in the pipeline; why the fight against antimicrobial resistance is making slow progress
The availability of gene-editing tools such as Crispr has led to an explosion of unchecked DIY experiments in self-built labs
Value of labs and campuses soar after pandemic sparked greater interest in sector
International Edition
